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SUMMARY 
    The aim of this study was to estimate the power of a badger vaccine field trial using 
simulation techniques. The effects of sample size, sensitivity and specificity of the diagnostic 
test, transmission rate between unvaccinated badgers, Vaccine Efficacy for Susceptibility 
(VES) and Vaccine Efficacy for Infectiousness (VEI) on study power were determined. 
 
    The most striking result was the large effect of the specificity of the diagnostic test on 
study power. Sample size had a small effect on power. Study power increased with increasing 
transmission rate between non-vaccinated badgers. Changes in VES had a higher impact on 
power than changes in VEI. 
 
    In summary, study power in group randomized trials depends not only on sample size but 
on many other parameters. In the current vaccine trial, power was highly dependent on the 
specificity of the diagnostic test. Therefore, it is critical that the diagnostic test used in the 
badger vaccine trial is optimized to maximise test specificity. 
 
 
INTRODUCTION 
 
    Badgers (Meles meles) are an important reservoir of Mycobacterium bovis for cattle in 
Ireland and the United Kingdom and as a result, eradication of bovine tuberculosis (bTB) 
becomes likely impossible without measures to prevent cattle-to-badger transmission (More, 
2009). In a recent Irish study, 36% of badgers were found to be infected with bTB (Murphy 
et al., 2010). In 2001, Ireland initiated a 10-year work programme investigating the use of 
Bacillus Calmette-Guerin (BCG) vaccine in badgers as a medium-long term strategy to assist 
with national bTB control and eradication (Corner et al., 2007; Lesellier et al., 2009). Based 
on a series of initial experimental studies in captive badgers, BCG vaccination in badgers was 
associated with a reduction in both the number and size of gross histological lesions (Corner 
et al., 2008∗, Corner et al., 2010). These pen-based studies are currently being extended, with 
the design and implementation of a field trial in Ireland to evaluate vaccine efficacy in wild 
badger populations (Aznar et al., 2011). 
 
    In traditional vaccine field trials, individuals are randomly allocated (individual 
randomization) to either a vaccine or a placebo treatment and the relative risk of acquiring 
infection is determined by comparing infection rates in vaccinated and non-vaccinated 
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individuals. This design is appropriate for non-communicable diseases because the 
probability that an individual will become infected only depends on their susceptibility. 
Individual randomized trials allow the estimation of vaccine effects that reduce the 
susceptibility of an individual to infection or VES (Vaccine Efficacy for Susceptibility). This 
is also known as the direct effect of vaccination (Halloran et al., 1999). When dealing with 
infectious diseases, however, the likelihood that an individual will become infected depends 
not only on its susceptibility but also on the infectivity of surrounding individuals. The 
reduction in infectivity achieved by vaccination is known as Vaccine Efficacy for 
Infectiousness, (VEI) and is the result of the indirect effects of the vaccination in vaccinated 
and non vaccinated individuals. With infectious diseases, group randomized trials are the 
design of choice, allowing estimates of both the reduction in susceptibility (VES) and 
infectiveness (VEI) (Riggs and Koopman, 2005), with herd immunity being the most 
important indirect effect. In a field trial to evaluate BCG vaccine efficacy in badgers, Aznar 
et al. (2011) outlined the use of group randomization to provide estimates of both VES and 
VEI based on incidence data from three badger populations vaccinated with BCG at different 
levels of vaccination coverage: 100%, 50% and 0%. VEI can be estimated using this design 
by varying the proportion of susceptible individuals across populations (Longini et al., 1998). 
In the badger vaccine trial, estimates of VEI may be particularly important, given the reported 
reduction in gross histological lesions (and, potentially, reduced infectiousness) in vaccinated 
badgers (Hayes et al., 2000, Corner et al., 2008). Aznar et al. (2011) have previously outlined 
how the combined effects of VES and VEI can be summarized using the Basic Reproduction 
Ratio (R0) estimated as a function of vaccination coverage (R(p)). 
 
    It is essential to estimate study power to determine whether a vaccine field trial design is 
sufficient to detect a difference in outcome of a particular size or larger between the 
vaccinated and non-vaccinated group (Riggs and Koopman, 2004). As outlined by Charvat et 
al. (2009), power calculations based on the comparison of two independent binomials in 
which indirect effects are not taken into account, can largely overestimate study power. The 
same study refers to these calculations as ‘naive’. In recognition of this concern, there have 
been recent changes both to trial design and to methodologies that are used to estimate 
sample size and power in these studies. In group randomized trials, where direct and indirect 
vaccine effects are each important, power depends on a range of factors. Riggs and Koopman 
(2004, 2005) looked at some of these factors including unit size (size of the groups), contact 
rate, external force of infection and infection duration. Computer simulation techniques are 
now frequently used to address study power estimation (Joines et al., 2000; Walters, 2004). 
 
    The aim of this paper is to estimate the power of a group randomized badger vaccine field 
trial designed to assess the effect of vaccination on M. bovis transmission in badgers using 
simulation techniques. The vaccine trial started in September 2009 and it will run for four 
years. The effects of sample size, sensitivity and specificity of the diagnostic test, 
transmission rate between badgers prior to the start of the trial, VES and VEI on study power 
are determined. Although sample size was determined prior to the start of the study based on 
logistical issues without potential for further expansion, power calculations are still relevant 
as other parameters affecting power, such as Se and Sp of the diagnostic test, could 
potentially be adjusted to optimize study power. 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
Vaccine trial design  
 
    The vaccine trial area comprised about 750 square kilometres and it was divided into three 
zones North to South: A, B and C with similar characteristics in terms of size, number of 
main badger setts, cattle herds, cattle and land classification type. Three vaccination levels: 
100%, 50% and 0% were allocated to zones A, B and C in a way that a gradient of 
vaccination coverage North to South was achieved. The vaccination trial started in September 
2009 and three trappings have been already carried out in the trial area. The middle zone 
(Zone B) has been vaccinated at 50% coverage, while Zones A and C were randomly 
allocated to a 100% and 0% vaccination coverage. Vaccination within Zone B has and will be 
done randomly at an individual level (Aznar et al., 2011). Badgers have been trapped twice a 
year since the beginning of the trial. The first time badgers are trapped, they are allocated to a 
vaccine /placebo treatment. The treatment will be repeated on a yearly basis and the trial will 
run for four years since the start in 2009. 
 
 
The model 
 
    The total number of expected newly infected vaccinated and non-vaccinated badgers (E(C)) 
at the end of every time interval (Δt or time between two subsequent trappings) were 
simulated using the cumulative binomial distribution with parameters (s, p), where s is the 
total number of susceptible badgers caught in each of the trial zones at the beginning of each 
time interval Δt, and p is the probability that each of these badgers will become infected 
during that time interval. E(C) was simulated by drawing a random number (between 0 and 1) 
from a uniform distribution and next, using the random number, s and p, the smallest integer 
E(C) is determined such that the binomial cumulative distribution function evaluated at E(C) 
is equal to or exceeds that random number (this is implemented as the BIN.INV function in 
Excel 2010 and as the CRITBINOM function in earlier versions). This procedure assures a 
random draw from a binomial distribution with parameters s and p. The probability of each of 
the badgers becoming infected (p) was dependent on the transmission parameter β, the 
fraction of infected vaccinated badgers (Fv) and the prevalence (Prev) of infection in the area 
where each badger was located during each time interval (Aznar et al., 2011).  
 
    Model parameterisation was determined based on expert opinion and/or data available at 
the time of model construction (see Table 1), as follows: 
• Three hundred badgers were used in the simulation model including 120, 60 and 120 
in zones A, B and C, respectively, based on the figures obtained during the first 
trapping exercise (120, 64 and 115 in zones A, B and C, respectively).  
• The percentage of badgers re-trapped was set at 70%. No data was available at the 
time of the start of the study on re-trapping as only one trapping exercise had been 
carried out in the vaccine trial area. The figure of 70% was based on expert opinion 
based on previous trappings in other areas. 
• The initial prevalence for the three trial zones was set at 30%. In zone A, where no 
vaccination will be implemented, the prevalence was assumed to remain constant until 
the end of the trial. In zone B, where 50% vaccination will occur, prevalence was 
expected to reduce to 20% at the 7th and 8th trapping. In zone C, where we assumed all 
animals were vaccinated, prevalence was set to 20% at the second trapping, and to 
10% and 5% at the fourth and seventh trappings, respectively. 
• The fraction of susceptible and infected badgers vaccinated was set to 0% in zone A. 
In zone B, this fraction was increased from 30% to 40% at the 5th trapping. In zone C, 
this fraction was increased from 60% to 70% in the 5th trapping, and then to 80% in 
the 6th and subsequent trappings. 
    Based on the simulated dataset and using the methodology described by Aznar et al. (2011) 
to estimate the four transmission parameters, βUU, βVV, βUV and βVU, the transmission rate 
between non-vaccinated badgers was estimated to be βUU=0.1.  
 
Table 1. Table showing simulated dataset consisting on: trapping exercise number, zone of 
the vaccine trial, fraction of susceptible vaccinated badgers (fs), fraction of infected 
vaccinated badgers (fi) and prevalence used during the model simulations. 
Trapping  Zone Vaccine Status fs* fi** Prevalence 
2 A 0 0 0 0.3 
3 A 0 0 0 0.3 
4 A 0 0 0 0.3 
5 A 0 0 0 0.3 
6 A 0 0 0 0.3 
7 A 0 0 0 0.3 
8 A 0 0 0 0.3 
2 B 0 0.3 0.3 0.3 
3 B 0 0.3 0.3 0.3 
4 B 0 0.3 0.3 0.3 
5 B 0 0.4 0.4 0.3 
6 B 0 0.4 0.4 0.3 
7 B 0 0.4 0.4 0.2 
8 B 0 0.4 0.4 0.2 
2 C 0 0.6 0.6 0.2 
3 C 0 0.6 0.6 0.2 
4 C 0 0.6 0.6 0.1 
5 C 0 0.7 0.7 0.1 
6 C 0 0.8 0.8 0.1 
7 C 0 0.8 0.8 0.05 
8 C 0 0.8 0.8 0.05 
2 A 1 0 0 0.3 
3 A 1 0 0 0.3 
4 A 1 0 0 0.3 
5 A 1 0 0 0.3 
6 A 1 0 0 0.3 
7 A 1 0 0 0.3 
8 A 1 0 0 0.3 
2 B 1 0.3 0.3 0.3 
3 B 1 0.3 0.3 0.3 
4 B 1 0.3 0.3 0.3 
5 B 1 0.4 0.4 0.3 
6 B 1 0.4 0.4 0.3 
7 B 1 0.4 0.4 0.2 
8 B 1 0.4 0.4 0.2 
2 C 1 0.6 0.6 0.2 
3 C 1 0.6 0.6 0.2 
4 C 1 0.6 0.6 0.1 
5 C 1 0.7 0.7 0.1 
6 C 1 0.8 0.8 0.1 
7 C 1 0.8 0.8 0.05 
8 C 1 0.8 0.8 0.05 
 
fs*=Fraction of susceptible badgers that are vaccinated 
fi**= Fraction of infected badgers that are vaccinated 
 
 
The simulation process 
 
    The badger vaccine trial was designed to run for four years with two trapping exercises per 
year. Therefore, a dataset of 42 records was generated (7 subsequent trappings x 3 trial zones 
x 2 vaccine status), comprising the total number of newly infected vaccinated and non-
vaccinated badgers in each of the three trial zones at the end of each subsequent trapping. The 
final dataset was read into SAS (SAS 9.1, SAS Institute Inc., 2005) and a simulation process 
was set up by means of a macro. We performed 1,000 simulations for each set of conditions 
(see following section). In each simulation, a new random number was drawn and a t-test was 
used to test for the null hypothesis of the transmission parameters between vaccinated (βVV) 
and non-vaccinated badgers (βUU) being equal. The power of the study was then estimated as 
the fraction of simulations in which the null hypothesis was rejected at a 0.05 level of 
significance. 
 
 
The scenarios tested 
 
Se and Sp of the diagnostic test: The power of the study was estimated for all combinations 
of sensitivity (Se) between 0 and 100%, and specificity (Sp) between 98 and 100% at 
increments of 5% and 0.2%, respectively, assuming an initial transmission between non-
vaccinated badgers of βUU=0.1 and a vaccine effect on susceptibility (VES) and infectivity 
(VEI) of 80%. The same simulations were repeated assuming VES and VEI were each 40%. 
 
Sample size: The study sample size was determined by both the expected number of trapped 
badgers and by re-trapping percentages. We explored the effects of sample size on study 
power by modifying both parameters so that the total number of re-trapped badgers varied 
from 10% to 100% of the expected number of badgers (120/60/120). We assumed an initial 
transmission between non-vaccinated badgers of βUU=0.1(this is the figure obtained based on 
the simulated data), a Se of 40% and a Sp of 99.9%. Vaccine effect on susceptibility (VES) 
and infectivity (VEI) was set at 80% (we assumed that vaccination conferred protection 
against the infection to 80% of the vaccinated badgers and infectiousness of vaccinated 
badgers was reduced by 80%). The same simulations were repeated assuming VES and VEI 
equal to 40%. To investigate the decrease in power observed for larger samples sizes, the 
same simulations were run assuming a perfect test with 100% Se and 100% Sp. 
 
Initial transmission: We estimated power using a fixed Se and Sp of 40% and 99.9%, 
respectively, for vaccine effects (VEI and VES) of 80% and 40%, and for βUU values of 0.3, 
0.2, 0.1, 0.005 and 0.025. We aimed to see the effect of variations in the βUU=0.1 obtained 
from the simulated data on study power.  
 
Vaccine effects on susceptibility and infectivity: Using a Se of 40% and a Sp of 99.9% and 
fixing VEI at 80%, power was estimated for different βUU values (0.3, 0.2, 0.1, 0.005 and 
0.025) and two values of Vaccine Efficacy for Susceptibility: VES=80% and VES=40%. The 
same simulations were done but in this case we fixed VES at 80% and looked at the effect of 
modifying VEI from 40% to 80% on study power when βUU values varied from 0.025 to 0.3.  
 
Outputs 
 
    Two dimensional graphs were built using the software Mathematica® 6.0 (Wolfram 
Research, Champaign, IL). To obtain the function that best fitted our data, we used Stata® 
version 10 (Stata Corp, College Station, TX, USA) to fit a generalized linear model (GLM) 
with different links of the binomial family. The link with the lowest AIC was selected. Line 
graphs were built using Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA, USA). 
 
 
RESULTS 
 
 
Study power for different sensitivity and specificity of the diagnostic test 
 
    The study power for different Se and Sp values of the diagnostic test are shown in Figures 
1 and 2. A decrease in Sp has much bigger impact on power than a decrease in Se. In Figure 1 
it can be seen that the power of the study decreases sharply to around 5% when the Sp is 
98.0% independently of the Se of the test. The effect of the Se on study power is much lower 
and given a Sp of 98.8 remains above 50% even when the Se is 40%. A VES and VEI of 80% 
were assumed in this graph. Similar results were obtained when we assumed a VES and VEI 
of 40%. This is shown in Figure 2 where for a Sp of 99.8% and a Se of 40%, study power 
was 45%. 
 
 
 
  
Fig. 1 Three dimensional plot showing the power of the badger vaccine trial as a function of 
the sensitivity (Se) and specificity (Sp) of the diagnostic test. βuu was set at 0.1, VEI and VES 
at 80%. 
 
 
Fig. 2 Three dimensional plot showing the power of the badger vaccine trial as a function of 
the sensitivity (Se) and specificity (Sp) of the diagnostic test. βuu was set at 0.1, VEI and VES 
to 40%. 
 
 
Study power for variations in sample size  
 
    The effect of a decrease in the expected number of total badgers re-trapped (120/60/120) is 
presented in Figure 3. Assuming a Se of 40%, a Sp of 99.9% and a transmission parameter 
for non-vaccinated badgers βUU=0.1, the study power was determined for two scenarios: both 
VES and VEI  equal to 40% and 80%, respectively, when the percentage of total badgers re-
trapped varied from 10% to 100%. Figure 3 shows an increase in study power as sample size 
increases from 10% to 30% and then a slow and small decrease as sample increases up to 
100%.  
 
To investigate reasons for the slow decrease in the study power observed as sample size 
increases, the same simulations were repeated using a perfect diagnostic test with 100% Se 
and 100% Sp. Then, it is shown that study power increases when sample size rises from 10% 
to 20% and remains constant up to 100% of the expected sample size (Figure 4). Assuming a 
perfect test, the study power varied from 79.8% to 85.9% when sample size increased from 
30 to 300 badgers and VES and VEI were equal to 40%. When VES and VEI were equal to 
80%, the study power varied from 91.2% to 95.8% as sample size went from 30 to 300 
badgers.  
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Fig. 3 Graph showing the study power as function of the total percentage of badgers re-
trapped and variation in vaccine efficacy. βuu was set at 0.1, VEI and VES to 80% (or 40%), 
Se at 40% and Sp at 99.9%. 
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Fig. 4 Graph showing the study power for variations in the total percentage of badgers re-
trapped. Sensitivity and specificity of the diagnostic test was set at 100%. Transmission 
between non-vaccinated badgers was 0.1%. The simulation process was carried out for both 
VES and VEI equal to 40% and VES and VEI equal to 80%. 
 
 
Study power for variations in the initial transmission 
 
    A transmission value of 0.1 was used in all previous calculations of study power. In order 
to see the effect of deviations from this value on study power, we ran our macro keeping all 
other parameters fixed except βUU. Figure 5 illustrates how the transmission rate between 
badgers prior to the start of the vaccine trial (βUU) affects study power. Assuming Se=40%, 
Sp=99.9% and VES and VEI=80%, the study power increases from 77% to 80% when βUU 
increases from 0.1 to 0.3 and decreases to 0.63 when transmission is four times smaller 
(0.025). Under the same conditions but assuming a VES and VEI of 40%, power varies from 
0.57 to 0.70 when βUU goes from 0.025 to 0.3. The power obtained when assuming an 80% 
reduction in susceptibility and infectivity due to vaccination were on average 73.4% versus 
an average of 63.4% when the vaccine effects reduction was 40%. In both cases, the power 
decreases as the transmission rate between non-vaccinated badgers decreases. 
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Fig. 5 Graph showing the power of the badger vaccine trial by transmission rate between non-
vaccinated badgers (βuu) assuming a sensitivity and specificity of the diagnostic test of Se= 
40% and Sp=99.9%. 
 
 
Study power for different vaccine effects on susceptibility and infectivity 
 
    To illustrate whether changes in the vaccine effect on susceptibility had higher, lower or 
equal impact on power than changes in the vaccine effect on infectivity, we ran our 
simulation process for the same range of βUU values as in the previous section but keeping 
VEI =80% (Figure 6) or VES =80% (Figure 7) while varying the opposite vaccine effect. Both 
graphs then show the study power when VES and VEI both equal 80% in a dark blue line 
(solid triangles) compared to the study power values when only one of the vaccine effects is 
80% and the other is set at 40% (green line with solid squares). 
The average study power when VEI is 80% and VES is 40% is 65% (green line with solid 
squares in Figure 6) compared to an average of 72.2% (showed by a green line with solid 
squares in Figure 7) when VEI is 40% and VES is 80%. If we compare these two averages 
with the average obtained when both vaccine effects are set to 80% (average power=73.4%), 
we can see then that changes in VES have a much higher impact on power than changes in 
VEI. This is also observed by looking at the proximity of both lines in Figure 7 compared to 
Figure 6. 
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Fig. 6 Graph showing the power of the badger vaccine trial by transmission rate between non-
vaccinated badgers (βUU) assuming a sensitivity and specificity of the diagnostic test of Se= 
40% and Sp=99.9% and an effect of vaccination in infectivity of 80%; % and 40%, 
respectively. 
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Fig. 7 Graph showing the power of the badger vaccine trial by transmission rate between non-
vaccinated badgers (βuu) assuming a sensitivity and specificity of the diagnostic test of Se= 
40% and Sp=99.9% and an effect of vaccination in susceptibility of 80%. 
 
 
DISCUSSION 
    Scientific evidence obtained from vaccine field trials has played an important role in public 
health, helping governments to plan successful vaccination programs. Estimating statistical 
power in a vaccine trial is of great importance. If done a priori (before the trial starts), the 
optimal sample size to be used in the trial can be estimated. Using this sample size can give 
assurance of having sufficient statistical power to detect a pre-determined vaccine effect if it 
does indeed exist, whilst avoiding any unnecessary waste of resources. In the badger vaccine 
trial the maximum sample size was determined based on logistical issues without potential 
for further expansion of the vaccine trial area. Nonetheless, power calculations were still 
relevant as other parameters affecting power, such as Se and Sp of the diagnostic test, could 
potentially be adjusted to optimize study power.  
 
    A simulation approach was used to estimate the power of the trial where the following 
assumptions were made: 
• The contact function is frequency rather than density-dependent. Riggs and Koopman 
(2004) show how in density-dependent models sample size has a much higher impact 
on study power than in frequency-dependent models. This is in agreement with the 
results obtained in our simulations. Power remained relatively constant, varying from 
70% to 87% when sample size increased from 30 to 300 badgers (assuming a perfect 
diagnostic test). De Jong et al. (1995) explain how for most animal diseases, a 
frequency-dependent contact rate function fits the data better than a density-dependent 
function. Therefore, our assumption seems reasonable. 
• The badger prevalence in the trial area was assumed to be 30%. A recent study carried 
out in Ireland, where comprehensive bacteriological culture methods had been used, 
detected a prevalence of 36.3% in badgers (Murphy et al., 2010). 
• The expected number of badgers being trapped in each trapping exercise was set to 
120, 60 and 120 for zones A, B and C, respectively. Although the three zones in the 
vaccine trial area were selected to have a similar number of main badger setts, 
trappings conducted prior to the start of the trial revealed a lower number of badgers 
in Zone B compared to zones A and C. 
• Data on the re-trapping percentage and the fraction of susceptible (fs) and infected (fi) 
vaccinated badgers were based on expert opinion. Although a sensitivity analysis was 
carried out to see the effect of changes on the re-trapping percentage, slower or faster 
changes in fs and fi were not explored. 
 
    The most striking result obtained during the simulations was the large effect of the 
specificity of the diagnostic test on study power. The minimum specificity required to 
achieve a power above 60% was 99.8%. The effect of the sensitivity on power was much 
smaller. Assuming both VES and VEI=80% and given a specificity of 99.8%, the power 
remained above 50% even when the sensitivity was 40%. These results have substantial 
implications in terms of the optimization of the diagnostic test to be used in the vaccine trial, 
showing that although specificity needs to be very high, there is some degree of flexibility in 
terms of the sensitivity of the diagnostic test. The effect of sample size on study power was 
deemed to be very small. The small decrease observed on power as sample size increased 
(Fig. 3) disappeared when a 100% Se and Sp test was assumed (Fig. 4). The decrease in 
power observed was proven to be an artefact.  
 
Decreasing VES and VEI both had a negative effect on power, but changes in VES had a 
larger impact on power than changes in VEI. For a βUU=0.1, a reduction in VEI  of 50% (from 
80% to 40%) resulted in a reduction in power from 77% to 73%, while the same reduction in 
VES led to a higher reduction in power, going from 77% to 62%. The reduction in power is 
not considered high in either case, nonetheless the effect of VES in power is something to 
consider because of the uncertainty around the biological mechanisms in which BCG vaccine 
works in badgers. Using BCG vaccine by the subcutaneous or mucosal routes in badgers, 
Corner et al. (2008) demonstrated a reduction in histological lesions in vaccinated badgers 
compared to non-vaccinated badgers but did not show individual protection against infection. 
This lack of protection has to be interpreted with caution as the challenging doses used during 
the experiments might not be representative of the natural infection dose. However, if the 
results obtained in the study are indicative of the real VES, study power could be somewhat 
compromised. 
 
    In summary, it can be concluded that study power in group randomized trials depends not 
only on sample size but on many other parameters. In the current vaccine trial, power was 
highly dependent on the specificity of the diagnostic test. Therefore, it is critical that the 
diagnostic test used in the badger vaccine trial is optimized to maximise test specificity.  
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